SecBot SecBot
8-K ·Filed Nov 2, 2026

ABBV

AbbVie Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed14d 6h ago SEC0001104659-26-121322
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor for any subsequent announcement of a new board appointment, but this departure is routine and unlikely to affect operations or strategy.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$286.00
T+0 close · Nov 2, 2026 · via day close
Latest settled
+2.76%
T+5 · $293.89 · next T+20 in 15d
Vs SPY
+3.35%
α at T+5
Latest observation
+4.12%
T+8 · FF3 residual α
  1. T+0 · Nov 3 $286.00entry
  2. T+1 · 13d ago +3.09%α +1.44% · $294.83
  3. T+5 · 7d ago +2.76%α +3.35% · $293.89
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AbbVie disclosed that Class II director Jennifer L. Davis resigned from the board effective November 2, 2026, following her appointment as CEO of Align Technology. The resignation is not due to any dispute with AbbVie. This is a routine board departure with no material financial impact.

Key Facts

  • Jennifer L. Davis, a Class II director, resigned from AbbVie's board effective November 2, 2026.
  • Resignation was due to her recent appointment as CEO of Align Technology, Inc.
  • The filing states the resignation is not the result of any dispute or disagreement with AbbVie.
  • No replacement was named in the filing.

Financial Impact

No financial impact; a single board member departure with no stated compensation or financial terms.

Risk Factors

  • Loss of a board member with relevant industry experience, though the filing indicates no disagreement.

Market Snapshot

Price
$288.87
Volume
40
Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (38 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-121322
Document: 0001104659-26-121322-index-headers.html0001104659-26-121322
Document: 0001104659-26-121322-index.html0001104659-26-121322
Document: 0001104659-26-121322.txt0001104659-26-121322

Track record

22 reports on ABBV

Performance horizon

7 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +27.21% at T+60 after the Apr 29, 2026 report. 7 of 9 went positive at some point.

Filters
  1. Nov 9, 20267d ago 144 Neutral 2/10 Entry $293.89 Now $294.55 +0.22% settles Dec 9
  2. Nov 2, 202614d ago 8-K Neutral 2/10 Viewing Entry $286.00 Now $294.55 +2.99% settles Dec 2
  3. Oct 30, 202617d ago 8-K Bullish 6/10 Entry $294.89 Now $294.55 −0.12% settles Nov 30
  4. Oct 29, 202619d ago Court Ruling Bullish 7/10 Entry $294.89 Now $294.55 −0.12% settles Nov 30
  5. Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $282.68 to $294.55 Now $294.55 +4.20% ▲ +4.20% +7.66% vs SPY
  6. Oct 15, 20264w ago 8-K Neutral 2/10 Entry $285.42 to $295.03 Now $294.55 +3.20% ▲ +3.37% +4.53% vs SPY
  7. Oct 5, 20266w ago 8-K Neutral 4/10 Entry $265.06 to $289.60 Now $294.55 +11.12% ▲ +9.26% +12.16% vs SPY
  8. Sep 28, 20267w ago Court Ruling Neutral 2/10 Entry $263.29 to $286.39 Now $294.55 +11.87% ▲ +8.77% +8.06% vs SPY
  9. Sep 14, 20269w ago Court Ruling Neutral Not scored Entry $261.43 to $272.69 Now $294.55 +12.67% ▲ +4.30% +1.33% vs SPY
  10. Sep 3, 202610w ago 8-K Neutral 4/10 Entry $260.21 to $262.82 Now $294.55 +13.20% ▲ +1.00% +2.19% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens Wed (11h 16m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026